Design and Synthesis of Potent Quinazolines As Selective β-Glucocerebrosidase Modulators

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2016 Sep 7

PMID 27598312

Citations 9

Authors

Jianbin Zheng

Long Chen

Michael Schwake

Richard B Silverman

Dimitri Krainc

Affiliations

Soon will be listed here.

Abstract

Gaucher's disease is a common genetic disease caused by mutations in the β-glucocerebrosidase (GBA1) gene that have been also linked to increased risk of Parkinson's disease and Lewy body dementia. Stabilization of misfolded mutant β-glucocerebrosidase (GCase) represents an important therapeutic strategy in synucleinopathies. Here we report a novel class of GCase quinazoline inhibitors, obtained in a high throughput screening, with moderate potency against wild-type GCase. Rational design and a SAR study of this class of compounds led to a new series of quinazoline derivatives with single-digit nanomolar potency. These compounds were shown to selectively stabilize GCase when compared to other lysosomal enzymes and to increase N370S mutant GCase protein concentration and activity in cell assays. To the best of our knowledge, these molecules are the most potent noniminosugar GCase modulators to date that may prove useful for future mechanistic studies and therapeutic approaches in Gaucher's and Parkinson's diseases.

Citing Articles

-Associated Parkinson's Disease Is a Distinct Entity.

Skrahin A, Horowitz M, Istaiti M, Skrahina V, Lukas J, Yahalom G Int J Mol Sci. 2024; 25(13).

PMID: 39000225 PMC: 11241486. DOI: 10.3390/ijms25137102.

Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson's disease.

Williams D, Glasstetter L, Jong T, Kapoor A, Zhu S, Zhu Y bioRxiv. 2024; .

PMID: 38712038 PMC: 11071283. DOI: 10.1101/2024.03.22.586364.

GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy.

Huh Y, Usnich T, Scherzer C, Klein C, Chung S J Mov Disord. 2023; 16(3):261-278.

PMID: 37302978 PMC: 10548077. DOI: 10.14802/jmd.23023.

Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models.

Burbulla L, Zheng J, Song P, Jiang W, Johnson M, Brundin P JCI Insight. 2021; 6(19).

PMID: 34622801 PMC: 8525588. DOI: 10.1172/jci.insight.148649.

Current Approaches and Tools Used in Drug Development against Parkinson's Disease.

Koszla O, Stepnicki P, Zieba A, Grudzinska A, Matosiuk D, Kaczor A Biomolecules. 2021; 11(6).

PMID: 34208760 PMC: 8235487. DOI: 10.3390/biom11060897.

References

Steet R, Chung S, Wustman B, Powe A, Do H, Kornfeld S . The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci U S A. 2006; 103(37):13813-8. PMC: 1564243. DOI: 10.1073/pnas.0605928103. View

Hruska K, Lamarca M, Scott C, Sidransky E . Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008; 29(5):567-83. DOI: 10.1002/humu.20676. View

Tekoah Y, Tzaban S, Kizhner T, Hainrichson M, Gantman A, Golembo M . Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Biosci Rep. 2013; 33(5). PMC: 3782720. DOI: 10.1042/BSR20130081. View

Tropak M, Kornhaber G, Rigat B, Maegawa G, Buttner J, Blanchard J . Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem. 2008; 9(16):2650-62. PMC: 2910749. DOI: 10.1002/cbic.200800304. View

Wang G, Reinkensmeier G, Zhang S, Zhou J, Zhang L, Zhang L . Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease. J Med Chem. 2009; 52(10):3146-9. DOI: 10.1021/jm801506m. View

Zheng W, Padia J, Urban D, Jadhav A, Goker-Alpan O, Simeonov A . Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A. 2007; 104(32):13192-7. PMC: 1936979. DOI: 10.1073/pnas.0705637104. View

Zunke F, Andresen L, Wesseler S, Groth J, Arnold P, Rothaug M . Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2. Proc Natl Acad Sci U S A. 2016; 113(14):3791-6. PMC: 4833265. DOI: 10.1073/pnas.1514005113. View

Schapira A, Olanow C, Greenamyre J, Bezard E . Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet. 2014; 384(9942):545-55. DOI: 10.1016/S0140-6736(14)61010-2. View

Butters T, Dwek R, Platt F . Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology. 2005; 15(10):43R-52R. DOI: 10.1093/glycob/cwi076. View

10.

Lo M, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M . Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem. 2004; 332(1):153-9. DOI: 10.1016/j.ab.2004.04.031. View

11.

Filippova E, Luan C, Dunne S, Kiryukhina O, Minasov G, Shuvalova L . Structural characterization of a hypothetical protein: a potential agent involved in trimethylamine metabolism in Catenulispora acidiphila. J Struct Funct Genomics. 2014; 15(1):33-40. PMC: 3955178. DOI: 10.1007/s10969-014-9176-z. View

12.

Marugan J, Zheng W, Motabar O, Southall N, Goldin E, Westbroek W . Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity. J Med Chem. 2011; 54(4):1033-58. PMC: 3103057. DOI: 10.1021/jm1008902. View

13.

Sybertz E, Krainc D . Development of targeted therapies for Parkinson's disease and related synucleinopathies. J Lipid Res. 2014; 55(10):1996-2003. PMC: 4173992. DOI: 10.1194/jlr.R047381. View

14.

Sawkar A, Cheng W, Beutler E, Wong C, Balch W, Kelly J . Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A. 2002; 99(24):15428-33. PMC: 137733. DOI: 10.1073/pnas.192582899. View

15.

Aguilar-Moncayo M, Isabel Garcia-Moreno M, Trapero A, Egido-Gabas M, Llebaria A, Garcia Fernandez J . Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: effect of structural modifications in their pharmacological chaperone potential towards β-glucocerebrosidase. Org Biomol Chem. 2011; 9(10):3698-713. DOI: 10.1039/c1ob05234a. View

16.

Matulis D, Kranz J, Salemme F, Todd M . Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry. 2005; 44(13):5258-66. DOI: 10.1021/bi048135v. View

17.

Grabowski G, Zimran A, Ida H . Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. Am J Hematol. 2015; 90 Suppl 1:S12-8. DOI: 10.1002/ajh.24063. View

18.

Grabowski G . Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008; 372(9645):1263-71. DOI: 10.1016/S0140-6736(08)61522-6. View

19.

Bennett L, Mohan D . Gaucher disease and its treatment options. Ann Pharmacother. 2013; 47(9):1182-93. DOI: 10.1177/1060028013500469. View

20.

Lin M, Farrer M . Genetics and genomics of Parkinson's disease. Genome Med. 2014; 6(6):48. PMC: 4085542. DOI: 10.1186/gm566. View